Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding
Sign Up to like & getrecommendations! Published in 2020 at "Neurocritical Care"
DOI: 10.1007/s12028-020-00968-6
Abstract: Background/Objective Intracranial bleeding (ICB) is a feared complication of systemic anticoagulation. Factor Xa inhibitors (FXaI) are used frequently due to their improved safety profile and predictable kinetics. Andexanet alfa was recently approved for emergent reversal… read more here.
Keywords: efficacy; intracranial bleeding; complex concentrates; prothrombin complex ... See more keywords
Prothrombin, alone or in complex concentrates or plasma, reduces bleeding in a mouse model of blood exchange-induced coagulopathy
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-49552-9
Abstract: Prothrombin complex concentrates (PCC) are fractionated plasma protein drugs that reverse warfarin anticoagulation. PCC may control more general bleeding. We sought to identify the dominant procoagulant factor in PCC in vivo. We tested PCC or… read more here.
Keywords: prothrombin; pcc; aso fii; complex concentrates ... See more keywords
3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Thrombosis and Haemostasis"
DOI: 10.1055/s-0042-1758653
Abstract: Long-term anticoagulation is used worldwide to prevent or treat thrombotic events. Anticoagulant therapy using vitamin K antagonists (VKAs) is well established; however, anticoagulants carry an increased risk of potentially life-threatening bleeding. In cases of bleeding… read more here.
Keywords: associated coagulopathy; meta analysis; complex concentrates; factor ... See more keywords
Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.13815
Abstract: Essentials Prothrombin complex concentrates (PCCs) may reverse the effect of factor Xa (FXa) inhibitors. We conducted an open‐label, randomized, placebo‐controlled, three‐period crossover study in 15 subjects. Both PCCs rapidly reversed apixaban‐mediated decreases in mean endogenous… read more here.
Keywords: period crossover; crossover study; three period; complex concentrates ... See more keywords
Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296221078842
Abstract: Direct oral factor Xa inhibitors (DXIs) are approved for use in adult patients with non-valvular heart disease for stroke prevention, and the treatment/prevention of venous thromboembolism (VTE). Recent pediatric clinical trials have demonstrated safety and… read more here.
Keywords: complex concentrates; survey; hematology; reversal ... See more keywords
Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
Sign Up to like & getrecommendations! Published in 2020 at "Thrombosis Journal"
DOI: 10.1186/s12959-020-00228-9
Abstract: Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability.… read more here.
Keywords: prothrombin complex; anticoagulant effect; complex concentrates; rivaroxaban anticoagulant ... See more keywords